Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Treasury Shares: 2020-2025

Historic Treasury Shares for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $321,498.

  • Lyell Immunopharma's Treasury Shares fell 92.74% to $321,498 in Q3 2025 from the same period last year, while for Sep 2025 it was $321,498, marking a year-over-year decrease of 92.74%. This contributed to the annual value of $281,190 for FY2024, which is 86.43% down from last year.
  • Per Lyell Immunopharma's latest filing, its Treasury Shares stood at $321,498 for Q3 2025, which was down 15.77% from $381,671 recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Treasury Shares peaked at $9.1 million during Q1 2025, and registered a low of $281,190 during Q4 2024.
  • In the last 3 years, Lyell Immunopharma's Treasury Shares had a median value of $2.6 million in 2023 and averaged $3.2 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Treasury Shares skyrocketed by 323.92% in 2021, and later crashed by 92.74% in 2025.
  • Over the past 5 years, Lyell Immunopharma's Treasury Shares (Quarterly) stood at $2.6 million in 2021, then plummeted by 66.46% to $872,077 in 2022, then surged by 137.69% to $2.1 million in 2023, then slumped by 86.43% to $281,190 in 2024, then crashed by 92.74% to $321,498 in 2025.
  • Its Treasury Shares stands at $321,498 for Q3 2025, versus $381,671 for Q2 2025 and $9.1 million for Q1 2025.